Bryostatin enhances CD20 CAR-T therapy efficacy against B-cell lymphoma by overcoming trogocytosis-mediated antigen loss
Bryostatin enhances CD20 CAR‑T efficacy by counteracting trogocytosis‑driven antigen loss and upregulating CD20 expression, providing a promising strategy to overcome antigen escape in lymphoma therapy.
Authors
- Lin Wei (ORCID: https://orcid.org/0000-0001-7146-891X)
- Keran Sun
- Li Zhang (ORCID: https://orcid.org/0000-0003-1152-8962)
- Shuxia Song (ORCID: https://orcid.org/0009-0006-3612-0938)
- Ling Cui
Institutions
- Hebei Medical University (CN)
- Immune Regulation (United Kingdom) (GB)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-01-22
- DOI
- https://doi.org/10.3389/fimmu.2025.1748634
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Hebei Medical University